危重症成人静脉血栓栓塞预防:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入13项RCT共9619例危重症成人,比较药物、机械或联合预防VTE的疗效与安全性。结果显示,与对照相比,低分子肝素降低DVT发生率(OR 0.59),且可能优于普通肝素(OR 0.72);普通肝素和压缩装置可能降低DVT风险,但证据确定性较低。
要点
- 低分子肝素较对照显著降低危重症成人DVT发生率,证据确定性高。
- 低分子肝素较普通肝素可能更有效降低DVT,证据确定性中等。
- 普通肝素和压缩装置可能降低DVT风险,但证据确定性低。
核心结论
- 在危重症成人中,与对照治疗相比,低分子肝素降低DVT发生率,普通肝素和机械压缩装置可能降低DVT风险。
- 低分子肝素在降低DVT发生率方面可能优于普通肝素,应考虑作为血栓预防的主要药物。
- 联合药物与机械压缩装置的疗效和安全性不明确。
研究设计与样本
- 系统评价与网状Meta分析,纳入评估危重症患者血栓预防药物疗效的随机对照试验。
- 检索六个数据库(包括PubMed、EMBASE和Medline)自建库至2021年1月,纳入ICU患者接受药物、机械或联合治疗预防血栓的RCT。
- 共纳入13项RCT,9619例患者。
- 采用GRADE评级证据确定性。
主要发现
- 与对照治疗(无预防、安慰剂或仅弹力袜的复合终点)相比,低分子肝素降低DVT发生率(OR 0.59 [95% CrI 0.33-0.90];高确定性)。
- 与对照治疗相比,普通肝素可能降低DVT发生率(OR 0.82 [95% CrI 0.47-1.37];低确定性)。
- 与普通肝素相比,低分子肝素可能降低DVT(OR 0.72 [95% CrI 0.46-0.98];中等确定性)。
- 与对照治疗相比,压缩装置可能降低DVT风险(OR 0.85 [95% CrI 0.50-1.50];低确定性)。
- 与单独药物或机械治疗相比,联合治疗对DVT的影响不明确(极低确定性)。
临床怎么用
- 对于危重症成人,可优先考虑低分子肝素作为药物性血栓预防的主要选择。
- 普通肝素和机械压缩装置可作为备选,但需注意证据确定性较低。
- 联合药物与机械压缩装置的疗效和安全性不明确,临床决策需个体化。
局限性
- 联合药物与机械压缩装置的疗效和安全性不明确。
- 普通肝素和压缩装置降低DVT风险的证据确定性低。
- 联合治疗对比单独治疗的证据确定性极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critically ill adults are at increased risk of VTE, including DVT, and pulmonary embolism. Various agents exist for venous thromboprophylaxis in this population. RESEARCH QUESTION: What is the comparative efficacy and safety of prophylaxis agents for prevention of VTE in critically ill adults? STUDY DESIGN AND METHODS: Systematic review and network meta-analysis of randomized clinical trials (RCTs) evaluating efficacy of thromboprophylaxis agents among critically ill patients. We searched six databases (including PubMed, EMBASE, and Medline) from inception through January 2021 for RCTs of patients in the ICU receiving pharmacologic, mechanical, or combination therapy (pharmacologic agents and mechanical devices) for thromboprophylaxis. Two reviewers performed screening, full-text review, and extraction. We used the Grading of Recommendations Assessment, Development, and Evaluation to rate certainty of effect estimates. RESULTS: We included 13 RCTs (9,619 patients). Compared with control treatment (a composite of no prophylaxis, placebo, or compression stockings only), low-molecular-weight heparin (LMWH) reduced the incidence of DVT (OR, 0.59 [95% credible interval [CrI], 0.33-0.90]; high certainty) and unfractionated heparin (UFH) may reduce the incidence of DVT (OR, 0.82 [95% CrI, 0.47-1.37]; low certainty). LMWH probably reduces DVT compared with UFH (OR, 0.72 [95% CrI, 0.46-0.98]; moderate certainty). Compressive devices may reduce risk of DVT compared with control treatments; however, this is based on low-certainty evidence (OR, 0.85 [95% CrI, 0.50-1.50]). Combination therapy showed unclear effect on DVT compared with either therapy alone (very low certainty). INTERPRETATION: Among critically ill adults, compared with control treatment, LMWH reduces incidence of DVT, whereas UFH and mechanical compressive devices may reduce the risk of DVT. LMWH is probably more effective than UFH in reducing incidence of DVT and should be considered the primary pharmacologic agent for thromboprophylaxis. The efficacy and safety of combination pharmacologic therapy and mechanical compressive devices were unclear. TRIAL REGISTRY: Open Science Framework; URL: https://osf.io/694aj.
引用
- Fernando SM, Tran A, Cheng W, et al. VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. Chest. 2021. PMID: 34419428. doi:10.1016/j.chest.2021.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。